drugset / Trial / NCT00955006

Immune Response to an HIV DNA Plasmid Vaccine Prime Followed by Adenovirus Boost in HIV-uninfected Individuals

NCT00955006

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of the study is to determine the safety of mucosal immune responses to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.

Timeline

Start
2011-05
Primary completion
2013-09
Completion
2017-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject VRC-HIVADV014-00-VP Vaccine Intramuscular
Subject VRC-HIVDNA016-00-VP Vaccine Intramuscular